Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to kill them all. The AI drug discoverer’s oral small molecule was able to ...
A multidisciplinary team integrated clinical need, cancer biology, and microfluidic bioengineering to advance ...
Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depend on the ability to deliver tiny particles known as aerosols to the correct location in ...
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...
Research presented by Professor Cecilia Johansson of Imperial College London has linked early type I interferon signalling in ...
Harish Narasimhan receives funding from the National Heart, Lung, and Blood Institute at the National Institutes of Health, USA. The long-term effects of respiratory viral infections such as COVID-19 ...
Penn Engineers have discovered a novel means of directing lipid nanoparticles (LNPs), the revolutionary molecules that delivered the COVID-19 vaccines, to target specific tissues, presaging a new era ...
Scientists have made a key breakthrough for treating respiratory diseases by developing a new drug delivery system that transports genetic therapies directly to the lungs, opening promising ...
Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback